Full Press Release Details
NIH SELECTS REGENERON FOR KNOCKOUT MOUSE PROJECT Regeneron Will Use its VelociGene Technology to Target 3,500 Genes Over Five Years, Providing New Models of Human Diseases.
REGN
NIH SELECTS REGENERON FOR KNOCKOUT MOUSE PROJECT Regeneron Will Use its VelociGene Technology to Target 3,500 Genes Over Five Years, Providing New Models of Human Diseases
Key Takeaway: NIH SELECTS REGENERON FOR KNOCKOUT MOUSE PROJECT Regeneron Will Use its VelociGene Technology to Target 3,500 Genes Over Five Years, Providing New Models of Human Diseases
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema